These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28943195)

  • 1. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
    Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
    J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
    Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
    Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy.
    Guerassimoff L; Ferrere M; Van Herck S; Dehissi S; Nicolas V; De Geest BG; Nicolas J
    J Control Release; 2024 May; 369():376-393. PubMed ID: 38554772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
    Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
    Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chain length impact on the retro Diels-Alder mediated release of gemcitabine from hybrid nanoparticles towards pancreatic cancer therapy.
    Oluwasanmi A; Lindsay S; Curtis A; Perrie Y; Hoskins C
    Int J Pharm; 2023 Sep; 644():123304. PubMed ID: 37572860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer cell membrane-modified Soluplus® micelles for gemcitabine delivery to pancreatic cancer using a prodrug approach.
    Pereira-Silva M; Diaz-Gomez L; Blanco-Fernandez B; Ferreirós A; Veiga F; Concheiro A; Paiva-Santos AC; Alvarez-Lorenzo C
    Int J Pharm; 2024 Sep; 662():124529. PubMed ID: 39084580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
    Sloat BR; Sandoval MA; Li D; Chung WG; Lansakara-P DS; Proteau PJ; Kiguchi K; DiGiovanni J; Cui Z
    Int J Pharm; 2011 May; 409(1-2):278-88. PubMed ID: 21371545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
    Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
    Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
    Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
    Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
    Dalla Pozza E; Lerda C; Costanzo C; Donadelli M; Dando I; Zoratti E; Scupoli MT; Beghelli S; Scarpa A; Fattal E; Arpicco S; Palmieri M
    Biochim Biophys Acta; 2013 May; 1828(5):1396-404. PubMed ID: 23384419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
    Smith RC; Bulanadi JC; Gill AJ; Rye KA; Hugh T; Proschogo N; Smith SF; Phillips L; Gong X; Julovi SM; Xue A; Moghaddam MJ
    Cancer Lett; 2020 Dec; 495():112-122. PubMed ID: 32949679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.
    Poon C; He C; Liu D; Lu K; Lin W
    J Control Release; 2015 Mar; 201():90-9. PubMed ID: 25620067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer.
    Dora CP; Kushwah V; Yadav V; Kuche K; Jain S
    Mol Pharm; 2024 Jun; 21(6):2699-2712. PubMed ID: 38747900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.
    Das M; Li J; Bao M; Huang L
    AAPS J; 2020 Jun; 22(4):88. PubMed ID: 32572645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
    Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
    Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles.
    Rodriguez-Ruiz V; Maksimenko A; Anand R; Monti S; Agostoni V; Couvreur P; Lampropoulou M; Yannakopoulou K; Gref R
    J Drug Target; 2015; 23(7-8):759-67. PubMed ID: 26453171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.